Infliximab for Rheumatoid Arthritis in a Patient with Tuberculosis
- 17 August 2006
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (7) , 740-741
- https://doi.org/10.1056/nejmc053468
Abstract
Tumor necrosis factor α antagonists have been shown to be effective agents in the treatment of rheumatoid arthritis; however, they have also been shown to increase the risk of the reactivation of tuberculosis in patients with latent infection1,2 and may render the tuberculosis refractory to drug therapy.3,4 Decisions regarding the treatment of patients with refractory rheumatoid arthritis in the setting of active tuberculosis remain difficult.Keywords
This publication has 3 references indexed in Scilit:
- Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated TuberculosisClinical Infectious Diseases, 2005
- Tuberculosis following therapy with infliximab may be refractory to antibiotic therapyRheumatology, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001